Promises and challenges of personalized medicine to guide ARDS therapy
Abstract Identifying new effective treatments for the acute respiratory distress syndrome (ARDS), including COVID-19 ARDS, remains a challenge. The field of ARDS investigation is moving increasingly toward innovative approaches such as the personalization of therapy to biological and clinical sub-ph...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2021-11-01
|
| Series: | Critical Care |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13054-021-03822-z |
| _version_ | 1818343055268249600 |
|---|---|
| author | Katherine D. Wick Daniel F. McAuley Joseph E. Levitt Jeremy R. Beitler Djillali Annane Elisabeth D. Riviello Carolyn S. Calfee Michael A. Matthay |
| author_facet | Katherine D. Wick Daniel F. McAuley Joseph E. Levitt Jeremy R. Beitler Djillali Annane Elisabeth D. Riviello Carolyn S. Calfee Michael A. Matthay |
| author_sort | Katherine D. Wick |
| collection | DOAJ |
| description | Abstract Identifying new effective treatments for the acute respiratory distress syndrome (ARDS), including COVID-19 ARDS, remains a challenge. The field of ARDS investigation is moving increasingly toward innovative approaches such as the personalization of therapy to biological and clinical sub-phenotypes. Additionally, there is growing recognition of the importance of the global context to identify effective ARDS treatments. This review highlights emerging opportunities and continued challenges for personalizing therapy for ARDS, from identifying treatable traits to innovative clinical trial design and recognition of patient-level factors as the field of critical care investigation moves forward into the twenty-first century. |
| first_indexed | 2024-12-13T16:24:30Z |
| format | Article |
| id | doaj.art-2c6c7098eba946a6be310dfce60d01e8 |
| institution | Directory Open Access Journal |
| issn | 1364-8535 |
| language | English |
| last_indexed | 2024-12-13T16:24:30Z |
| publishDate | 2021-11-01 |
| publisher | BMC |
| record_format | Article |
| series | Critical Care |
| spelling | doaj.art-2c6c7098eba946a6be310dfce60d01e82022-12-21T23:38:38ZengBMCCritical Care1364-85352021-11-0125111510.1186/s13054-021-03822-zPromises and challenges of personalized medicine to guide ARDS therapyKatherine D. Wick0Daniel F. McAuley1Joseph E. Levitt2Jeremy R. Beitler3Djillali Annane4Elisabeth D. Riviello5Carolyn S. Calfee6Michael A. Matthay7Cardiovascular Research Institute, University of California San FranciscoBelfast Health and Social Care Trust, Royal Victoria Hospital and Wellcome-Wolfson Institute for Experimental Medicine, Queen’s University BelfastDivision of Pulmonary, Allergy, and Critical Care Medicine, Stanford UniversityCenter for Acute Respiratory Failure and Division of Pulmonary, Allergy, and Critical Care Medicine, Columbia UniversityDepartment of Intensive Care, FHU SEPSIS, and RHU RECORDS, Hôpital Raymond Poincaré (APHP)Harvard Medical School and Division of Pulmonary, Critical Care, and Sleep Medicine, Beth Israel Deaconess Medical CenterCardiovascular Research Institute, University of California San FranciscoCardiovascular Research Institute, University of California San FranciscoAbstract Identifying new effective treatments for the acute respiratory distress syndrome (ARDS), including COVID-19 ARDS, remains a challenge. The field of ARDS investigation is moving increasingly toward innovative approaches such as the personalization of therapy to biological and clinical sub-phenotypes. Additionally, there is growing recognition of the importance of the global context to identify effective ARDS treatments. This review highlights emerging opportunities and continued challenges for personalizing therapy for ARDS, from identifying treatable traits to innovative clinical trial design and recognition of patient-level factors as the field of critical care investigation moves forward into the twenty-first century.https://doi.org/10.1186/s13054-021-03822-zAcute respiratory distress syndromeAcute lung injuryPersonalized medicineCOVID-19Clinical trials |
| spellingShingle | Katherine D. Wick Daniel F. McAuley Joseph E. Levitt Jeremy R. Beitler Djillali Annane Elisabeth D. Riviello Carolyn S. Calfee Michael A. Matthay Promises and challenges of personalized medicine to guide ARDS therapy Critical Care Acute respiratory distress syndrome Acute lung injury Personalized medicine COVID-19 Clinical trials |
| title | Promises and challenges of personalized medicine to guide ARDS therapy |
| title_full | Promises and challenges of personalized medicine to guide ARDS therapy |
| title_fullStr | Promises and challenges of personalized medicine to guide ARDS therapy |
| title_full_unstemmed | Promises and challenges of personalized medicine to guide ARDS therapy |
| title_short | Promises and challenges of personalized medicine to guide ARDS therapy |
| title_sort | promises and challenges of personalized medicine to guide ards therapy |
| topic | Acute respiratory distress syndrome Acute lung injury Personalized medicine COVID-19 Clinical trials |
| url | https://doi.org/10.1186/s13054-021-03822-z |
| work_keys_str_mv | AT katherinedwick promisesandchallengesofpersonalizedmedicinetoguideardstherapy AT danielfmcauley promisesandchallengesofpersonalizedmedicinetoguideardstherapy AT josephelevitt promisesandchallengesofpersonalizedmedicinetoguideardstherapy AT jeremyrbeitler promisesandchallengesofpersonalizedmedicinetoguideardstherapy AT djillaliannane promisesandchallengesofpersonalizedmedicinetoguideardstherapy AT elisabethdriviello promisesandchallengesofpersonalizedmedicinetoguideardstherapy AT carolynscalfee promisesandchallengesofpersonalizedmedicinetoguideardstherapy AT michaelamatthay promisesandchallengesofpersonalizedmedicinetoguideardstherapy |